Samsung to invest $10 million in US-based C2N Diagnostics

C2N offers advanced blood test solutions for the evaluation of brain health, especially Alzheimer’s disease

(Courtesy of Getty Images) 
(Courtesy of Getty Images) 
Dae-Kyu Ahn 2
2025-03-13 14:38:58 powerzanic@hankyung.com
Korean Investors

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s disease diagnostics, suggesting the South Korean conglomerate’s foray into the diagnostics business.

Samsung C&T Corp., the de facto holding company of Samsung Group, announced on Thursday that it decided to invest $10 million in C2N through the Samsung Life Science Fund, jointly created by Samsung C&T, Samsung Biologics Co. and Samsung Bioepis Co. and managed by their affiliated investment arm Samsung Venture Investment Corp.

The investment is expected to pave the way for Samsung’s venture into the diagnostics technology sector, said Kim Jay-woo, Samsung C&T's executive vice president.

Samsung C&T is considering advancing into the diagnostics business, separate from its bio subsidiaries’ contract development and manufacturing organization (CDMO) and biosimilar businesses.

C2N, a specialty diagnostics company for brain health, offers a blood test that is a safer, more cost-effective alternative to traditional diagnostic methods, such as amyloid PET-CT scans or cerebrospinal fluid tests, in accurately measuring Alzheimer's-related proteins, including amyloid-beta.

The US biotech company is seeking U.S. Food and Drug Administration (FDA) approval for its Alzheimer’s disease-specific fluid biomarker tests, which could become a game-changer in the early detection and treatment of the cognitive impairment.

“Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale and innovate next-generation diagnostic tests that can improve patients’ lives,” C2N CEO Dr. Joel Braunstein said in a statement.

Early detection and biomarker-based diagnostics are critical to the treatment of cognitive impairment, especially since global Alzheimer’s cases are expected to rise sharply in the coming decades.

Samsung’s investment follows a series of funding rounds supporting C2N’s biomarker research and diagnostic test development.

In September 2024, the company secured a $15 million investment from the GHR Foundation to develop a tau tangles pathology test, which could further enhance the accuracy of Alzheimer’s staging.

C2N also received $7 million from the Alzheimer’s Drug Discovery Foundation earlier last year.

The Samsung Life Science Fund was established to accelerate growth in biopharmaceuticals, diagnostics and innovative healthcare technologies.

By targeting companies like C2N, the fund aims to strengthen Samsung’s presence in the global life sciences sector and position it as a key player in precision medicine.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
Sookyung Seo edited this article.

Samsung Life Science invests in US biotech firm Latus Bio

Samsung Life Science invests in US biotech firm Latus Bio

Samsung Bioepis headquarters (Courtesy of Samsung Bioepis)  Samsung Life Science Fund, managed by Samsung Group’s venture investment arm, has invested in US biotechnology firm Latus Bio Inc. during the latter’s Series A funding round raising $54 million, according to the US com

Samsung invests in BrickBio in US

Samsung invests in BrickBio in US

Samsung Bioepis Songdo headquarters Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technologies company BrickBio.The Samsung Life Science Fund is a venture investment fund jointly formed by Samsung C&a

Samsung targets gene therapy sector through US investments

Samsung targets gene therapy sector through US investments

(File photo, courtesy of Samsung Biologics) Samsung Group is targeting the gene therapy business through investments in US biotechnology companies as the leading South Korean conglomerate is seeking new growth engines for its medical units.The Life Science Fund established by the group’s

Samsung Biologics to invest $1.5 bn for 5th CDMO factory

Samsung Biologics to invest $1.5 bn for 5th CDMO factory

Samsung Biologics headquarters in Incheon, South Korea (Courtesy of Samsung Biologics) Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investment as the construction of its fourth plant, the world's lar

Samsung’s Life Science Fund invests in US biotech Jaguar Gene Therapy

Samsung’s Life Science Fund invests in US biotech Jaguar Gene Therapy

Samsung Biologics' third plant in Songdo, Incheon Samsung Group’s 150 billion won ($124 million) Life Science Fund launched last year has chosen a leading US gene therapy development company as its first investment target.Samsung C&T Corp. and Samsung Biologics Co., the joint operator

(* comment hide *}